Topical Tacrolimus in Vitiligo: Consensus Paper from the Pigmentary Disorders Society
Rashmi Sarkar,1 Sunil Dogra,2 Keshavamurthy Vinay,2 Surabhi Sinha,3 Vignesh R Narayan,4 Muthu Sendhil Kumaran,2 Indrashis Podder,5 Soumya Jagadeesan,6 Mala Bhalla,7 Anupam Das,8 Ridhima Lakhani,9 Richa Sharma,10 Shyamanta Barua,11 Vijay K Somani,12 D M Thappa,13 Venkataram Mysore,14 Bhavesh Swarnkar...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-12-01
|
| Series: | Clinical, Cosmetic and Investigational Dermatology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/topical-tacrolimus-in-vitiligo-consensus-paper-from-the-pigmentary-dis-peer-reviewed-fulltext-article-CCID |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850063335898218496 |
|---|---|
| author | Sarkar R Dogra S Vinay K Sinha S Narayan VR Kumaran MS Podder I Jagadeesan S Bhalla M Das A Lakhani R Sharma R Barua S Somani VK Thappa DM Mysore V Swarnkar B |
| author_facet | Sarkar R Dogra S Vinay K Sinha S Narayan VR Kumaran MS Podder I Jagadeesan S Bhalla M Das A Lakhani R Sharma R Barua S Somani VK Thappa DM Mysore V Swarnkar B |
| author_sort | Sarkar R |
| collection | DOAJ |
| description | Rashmi Sarkar,1 Sunil Dogra,2 Keshavamurthy Vinay,2 Surabhi Sinha,3 Vignesh R Narayan,4 Muthu Sendhil Kumaran,2 Indrashis Podder,5 Soumya Jagadeesan,6 Mala Bhalla,7 Anupam Das,8 Ridhima Lakhani,9 Richa Sharma,10 Shyamanta Barua,11 Vijay K Somani,12 D M Thappa,13 Venkataram Mysore,14 Bhavesh Swarnkar15 1Department of Dermatology, Lady Hardinge Medical College and Associated KSCH and SSK Hospital, New Delhi, India; 2Department of Dermatology Venereology & Leprology, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, India; 3Department of Dermatology, Lady Hardinge Medical College and Associated Hospitals, New Delhi, India; 4Department of Dermatology Venereology and Leprology, MS Ramaiah Medical College, Bangalore, Karnataka, India; 5Department of Dermatology, CMSDH, Kolkata, West Bengal, India; 6Department of Dermatology, Amrita Institute of Medical Sciences, Kochi, Kerala, India; 7Department of Dermatology, Government Medical College and Hospital, Chandigarh, India; 8Department of Dermatology, KPC Medical College and Hospital, Kolkata, West Bengal, India; 9Consultant Dermatologist, Department of Dermatology, Fortis Hospitals, Shalimar Bagh, New Delhi, India; 10Consultant Dermatologist, Twacha Skin Clinic, New Delhi, India; 11Department of Dermatology, Assam Medical College & Hospital, Dibrugarh, Assam, India; 12Consultant Dermatologist, Dermatrendz, Hyderabad, Telangana, India; 13Department of Dermatology and STD, JIPMER, Puducherry, India; 14Consultant Dermatologist Venkat Center for Skin ENT and Plastic Surgery, Bengaluru, Karnataka, India; 15Consultant Dermatologist, Indore, Madhya Pradesh, IndiaCorrespondence: Rashmi Sarkar, Department of Dermatology, Lady Hardinge Medical College and Associated KSCH and SSK Hospital, New Delhi, India, Tel +91 9818244340, Email rashmisarkar@gmail.comBackground: Tacrolimus, a topical calcineurin inhibitor (TCI) with immunomodulatory effects, is considered a viable treatment option for vitiligo. A consensus building exercise was undertaken to determine the role and clinical utility of topical tacrolimus in the management of vitiligo using input from experts in the field of dermatology.Methods: Seventeen experts collaborated to create consensus statements using a modified Delphi methodology. A questionnaire on effectiveness, safety and utility of topical tacrolimus in different types of vitiligo, duration, frequency, monotherapy and combination and other aspects was shared, and a concordance rate of 75% was preset to have consensus. A physical meeting was conducted to discuss statements, which did not achieve consensus.Results: Amongst 34 statements derived from round one, consensus was not achieved for 9 statements. In the second round, consensus was achieved for 2/9 statements, hence in the physical meeting, discussion was done to reframe the remaining seven statements. Apart from these 34 statements, questions pertaining to “Vitiligo: types and presentation in clinical practice”, where consensus was not intended, are presented as descriptive statements.Conclusion: Topical tacrolimus ointment has a favorable risk benefit profile to be used as one of the first-line agents for vitiligo. Combination of topical tacrolimus and narrow band Ultraviolet-B (NBUVB) was recommended as an effective treatment for non-segmental vitiligo. Recommended frequency of application was once or twice daily for optimal results. Apart from a transient burning sensation, topical tacrolimus has a favorable safety profile.Keywords: topical calcineurin inhibitor, immunomodulatory, non-segmental vitiligo, depigmenting, autoimmune, autoreactive T cells, tacrolimus |
| format | Article |
| id | doaj-art-dc5cb8c530664387b67d7608b23ea10a |
| institution | DOAJ |
| issn | 1178-7015 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical, Cosmetic and Investigational Dermatology |
| spelling | doaj-art-dc5cb8c530664387b67d7608b23ea10a2025-08-20T02:49:37ZengDove Medical PressClinical, Cosmetic and Investigational Dermatology1178-70152024-12-01Volume 172875288698418Topical Tacrolimus in Vitiligo: Consensus Paper from the Pigmentary Disorders SocietySarkar RDogra SVinay KSinha SNarayan VRKumaran MSPodder IJagadeesan SBhalla MDas ALakhani RSharma RBarua SSomani VKThappa DMMysore VSwarnkar BRashmi Sarkar,1 Sunil Dogra,2 Keshavamurthy Vinay,2 Surabhi Sinha,3 Vignesh R Narayan,4 Muthu Sendhil Kumaran,2 Indrashis Podder,5 Soumya Jagadeesan,6 Mala Bhalla,7 Anupam Das,8 Ridhima Lakhani,9 Richa Sharma,10 Shyamanta Barua,11 Vijay K Somani,12 D M Thappa,13 Venkataram Mysore,14 Bhavesh Swarnkar15 1Department of Dermatology, Lady Hardinge Medical College and Associated KSCH and SSK Hospital, New Delhi, India; 2Department of Dermatology Venereology & Leprology, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, India; 3Department of Dermatology, Lady Hardinge Medical College and Associated Hospitals, New Delhi, India; 4Department of Dermatology Venereology and Leprology, MS Ramaiah Medical College, Bangalore, Karnataka, India; 5Department of Dermatology, CMSDH, Kolkata, West Bengal, India; 6Department of Dermatology, Amrita Institute of Medical Sciences, Kochi, Kerala, India; 7Department of Dermatology, Government Medical College and Hospital, Chandigarh, India; 8Department of Dermatology, KPC Medical College and Hospital, Kolkata, West Bengal, India; 9Consultant Dermatologist, Department of Dermatology, Fortis Hospitals, Shalimar Bagh, New Delhi, India; 10Consultant Dermatologist, Twacha Skin Clinic, New Delhi, India; 11Department of Dermatology, Assam Medical College & Hospital, Dibrugarh, Assam, India; 12Consultant Dermatologist, Dermatrendz, Hyderabad, Telangana, India; 13Department of Dermatology and STD, JIPMER, Puducherry, India; 14Consultant Dermatologist Venkat Center for Skin ENT and Plastic Surgery, Bengaluru, Karnataka, India; 15Consultant Dermatologist, Indore, Madhya Pradesh, IndiaCorrespondence: Rashmi Sarkar, Department of Dermatology, Lady Hardinge Medical College and Associated KSCH and SSK Hospital, New Delhi, India, Tel +91 9818244340, Email rashmisarkar@gmail.comBackground: Tacrolimus, a topical calcineurin inhibitor (TCI) with immunomodulatory effects, is considered a viable treatment option for vitiligo. A consensus building exercise was undertaken to determine the role and clinical utility of topical tacrolimus in the management of vitiligo using input from experts in the field of dermatology.Methods: Seventeen experts collaborated to create consensus statements using a modified Delphi methodology. A questionnaire on effectiveness, safety and utility of topical tacrolimus in different types of vitiligo, duration, frequency, monotherapy and combination and other aspects was shared, and a concordance rate of 75% was preset to have consensus. A physical meeting was conducted to discuss statements, which did not achieve consensus.Results: Amongst 34 statements derived from round one, consensus was not achieved for 9 statements. In the second round, consensus was achieved for 2/9 statements, hence in the physical meeting, discussion was done to reframe the remaining seven statements. Apart from these 34 statements, questions pertaining to “Vitiligo: types and presentation in clinical practice”, where consensus was not intended, are presented as descriptive statements.Conclusion: Topical tacrolimus ointment has a favorable risk benefit profile to be used as one of the first-line agents for vitiligo. Combination of topical tacrolimus and narrow band Ultraviolet-B (NBUVB) was recommended as an effective treatment for non-segmental vitiligo. Recommended frequency of application was once or twice daily for optimal results. Apart from a transient burning sensation, topical tacrolimus has a favorable safety profile.Keywords: topical calcineurin inhibitor, immunomodulatory, non-segmental vitiligo, depigmenting, autoimmune, autoreactive T cells, tacrolimushttps://www.dovepress.com/topical-tacrolimus-in-vitiligo-consensus-paper-from-the-pigmentary-dis-peer-reviewed-fulltext-article-CCIDtopical calcineurin inhibitorimmunomodulatorynon-segmental vitiligodepigmentingautoimmuneautoreactive t cells |
| spellingShingle | Sarkar R Dogra S Vinay K Sinha S Narayan VR Kumaran MS Podder I Jagadeesan S Bhalla M Das A Lakhani R Sharma R Barua S Somani VK Thappa DM Mysore V Swarnkar B Topical Tacrolimus in Vitiligo: Consensus Paper from the Pigmentary Disorders Society Clinical, Cosmetic and Investigational Dermatology topical calcineurin inhibitor immunomodulatory non-segmental vitiligo depigmenting autoimmune autoreactive t cells |
| title | Topical Tacrolimus in Vitiligo: Consensus Paper from the Pigmentary Disorders Society |
| title_full | Topical Tacrolimus in Vitiligo: Consensus Paper from the Pigmentary Disorders Society |
| title_fullStr | Topical Tacrolimus in Vitiligo: Consensus Paper from the Pigmentary Disorders Society |
| title_full_unstemmed | Topical Tacrolimus in Vitiligo: Consensus Paper from the Pigmentary Disorders Society |
| title_short | Topical Tacrolimus in Vitiligo: Consensus Paper from the Pigmentary Disorders Society |
| title_sort | topical tacrolimus in vitiligo consensus paper from the pigmentary disorders society |
| topic | topical calcineurin inhibitor immunomodulatory non-segmental vitiligo depigmenting autoimmune autoreactive t cells |
| url | https://www.dovepress.com/topical-tacrolimus-in-vitiligo-consensus-paper-from-the-pigmentary-dis-peer-reviewed-fulltext-article-CCID |
| work_keys_str_mv | AT sarkarr topicaltacrolimusinvitiligoconsensuspaperfromthepigmentarydisorderssociety AT dogras topicaltacrolimusinvitiligoconsensuspaperfromthepigmentarydisorderssociety AT vinayk topicaltacrolimusinvitiligoconsensuspaperfromthepigmentarydisorderssociety AT sinhas topicaltacrolimusinvitiligoconsensuspaperfromthepigmentarydisorderssociety AT narayanvr topicaltacrolimusinvitiligoconsensuspaperfromthepigmentarydisorderssociety AT kumaranms topicaltacrolimusinvitiligoconsensuspaperfromthepigmentarydisorderssociety AT podderi topicaltacrolimusinvitiligoconsensuspaperfromthepigmentarydisorderssociety AT jagadeesans topicaltacrolimusinvitiligoconsensuspaperfromthepigmentarydisorderssociety AT bhallam topicaltacrolimusinvitiligoconsensuspaperfromthepigmentarydisorderssociety AT dasa topicaltacrolimusinvitiligoconsensuspaperfromthepigmentarydisorderssociety AT lakhanir topicaltacrolimusinvitiligoconsensuspaperfromthepigmentarydisorderssociety AT sharmar topicaltacrolimusinvitiligoconsensuspaperfromthepigmentarydisorderssociety AT baruas topicaltacrolimusinvitiligoconsensuspaperfromthepigmentarydisorderssociety AT somanivk topicaltacrolimusinvitiligoconsensuspaperfromthepigmentarydisorderssociety AT thappadm topicaltacrolimusinvitiligoconsensuspaperfromthepigmentarydisorderssociety AT mysorev topicaltacrolimusinvitiligoconsensuspaperfromthepigmentarydisorderssociety AT swarnkarb topicaltacrolimusinvitiligoconsensuspaperfromthepigmentarydisorderssociety |